/
Oncology
Head and Neck Cancer
159
Pipeline Programs↗
267
Active Trials↗
109
Companies Involved↗
Head and Neck Cancer is a highly competitive landscape with 159 programs across 109 companies. The most active players are AstraZeneca, Coordination Pharmaceuticals, Inc.. 41 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical21
Phase 118
Phase 279
Phase 341
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
105 of 140 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 140 classified programs, each share of the total. Modality classified for 94% of 159 pipeline programs.
Analysis
Trial Status
885
clinical trials
Completed375 · 42%
Recruiting142 · 16%
Terminated118 · 13%
Unknown status76 · 9%
Active, not recruiting70 · 8%
Not yet recruiting55 · 6%
Other49 · 6%
Clinical Trials
Trial Activity
885 trials
Page 1 of 59
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)